The effect of low molecular weight dextran on platelet deposition onto prosthetic materials.
Low molecular weight dextran (LMD) has recently been shown in a randomized, multicenter trial to improve early patency in difficult lower extremity vascular bypass. The question remained as to whether this effect was due to plasma volume expansion by LMD or to its effects on platelets and coagulation. To analyze this we have studied the effects of LMD on platelet-graft interactions using an ex vivo baboon shunt. Indium 111-labeled autologous platelet deposition on expanded polytetrafluoroethylene and knitted Dacron grafts was monitored at a flow rate of 25 ml/min for 21/2 hours. LMD was given by intravenous bolus at a dose of 5 ml/kg and was followed by a continuous infusion of 10 ml/hr. Flow through the shunt was started after the initial dextran bolus. Control studies were performed in a similar manner without dextran. An additional series of experiments was performed with a 5 to 10 ml/kg bolus of 5% human serum albumin to analyze the contribution of plasma volume expansion to platelet deposition in this model. The results revealed a significant (p less than 0.05) reduction in platelet deposition on both graft materials with the LMD infusion. No difference was seen between the control group and the albumin group. These studies provide direct in vivo evidence of the antiplatelet effect of LMD.
D000418:Albumins / Q000494:pharmacology; D000818:Animals; D001672:Biocompatible Materials; D001792:Blood Platelets / Q000187:drug effects*; D001807:Blood Vessel Prosthesis; D003911:Dextrans / Q000494:pharmacology*; D008297:Male; D010215:Papio; D010953:Plasma Volume; D010974:Platelet Aggregation / Q000187:drug effects*; D011093:Polyethylene Terephthalates; D014654:Vascular Patency / Q000187:drug effects
D000418:Albumins; D001672:Biocompatible Materials; D003911:Dextrans; D011093:Polyethylene Terephthalates